Navigation Links
AAOMS Updates BRONJ Position Paper
Date:1/22/2009

ROSEMONT, Ill., Jan. 22 /PRNewswire-USNewswire/ -- The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition. BRONJ appears as a non-healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer-related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO)

Written by the members of the distinguished AAOMS Task Force on BRONJ who prepared the original paper, the 2009 BRONJ Position Paper updates the staging and management strategies for BRONJ, and highlights the status of basic science research relating to this condition.

The 2009 Position Paper retains the case definition of BRONJ:

1. The patient is or has been treated with a bisphosphonate.

2. Exposed bone has been present in the maxillofacial region for more than eight weeks; and

3. There is no history of radiation therapy to the jaws.

While there is strong evidence supporting an association between IV bisphosphonate therapy for cancer-related conditions and BRONJ, the 2009 BRONJ Position Paper stresses that the relationship between oral or IV bisphosphonates for treating osteoporosis and BRONJ is more difficult to establish.

Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to:

1. The potency the bisphosphonate used in therapy; and

2. The length of exposure to bisphosphonates.

Other factors that may increase the risk of developing BRONJ include:

  • A history of inflammatory dental disease,
    '/>"/>

SOURCE American Association of Oral & Maxillofacial Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
2. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
3. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
4. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
5. Genmab Announces Updates on Phase III Cancer Studies
6. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. BioCryst Updates Peramivir Clinical Development Plan
11. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... results of a Phase 2b trial for Empatic(TM) on Wednesday, ... will be followed by a live webcast and conference call ... the call and webcast to discuss the results of this ...
... Pharmaceutical Major, Lupin Ltd. announced today the acquisition of ... mg). Lupin acquired the product from Oscient Pharmaceuticals on ... Court. Antara recorded net sales of US $ 70 ... $ 38.61 million for the product and related assets inclusive ...
Cached Medicine Technology:Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:7/11/2014)... 2014 AngelWeddingDress is now providing worldwide ... summer collections ”. When it comes to buying summer ... AngelWeddingDress with the unlimited stock of beautiful wedding gowns. ... its wonderful summer wedding gowns. , The company’s ... to keep pace with the newest fashion trends. The ...
(Date:7/11/2014)... American Farmer is proud to announce ... 15, 2014, at 8:30 am ET. , In this ... which are designed and formulated for use on a ... these products help the crop realize its maximum genetic ... grown. , The show also features UniSouth Genetics, a ...
(Date:7/11/2014)... 11, 2014 Alliance Labs announced that ... Innovations with Ed Begley Jr, airing later this year ... , In this episode, Innovations will explore DocuSol® Kids, ... sodium in polyethylene glycol base designed to give adolescents ... formulation functions as a hyperosmotic laxative by drawing water ...
(Date:7/11/2014)... 11, 2014 College athletes experiencing in-season ... of injury, but developed recurrent instability in 63% of ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... in providing the most optimal treatment plans for injured ... anterior shoulder instability event, and found that 33 (73%) ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... workers in the United States has risen, so has ... ,According to Vanderbilt infectious disease experts Timothy R. ... be provided to health care workers with latent TB ... particularly if they meet certain high-risk criteria. ...
... researchers has discovered a new protein called as P2 ... epithelial cells// that regulates the allergic airway inflammation. ... study that the adipocyte/macrophage fatty acid–binding protein aP2, which ... of fatty acids and has been previously linked to ...
... the open access journal Substance Abuse Treatment, Prevention and policy ... training treats the alcohol dependent patients better for a long ... by trained GPs who abstain from drinking alcohol is more ... basic training alone at the medical school. Also the ...
... duvets used by most Britons are packed with dust mites, fungus ... duvets it was found to contain up to 20,000 live house ... analysis of an 11-year unwashed duvet revealed over an ounce and ... faeces. ,In addition it was found that more than ...
... new research, the risk of heart diseases is reduced on ... the University of Bristol in the UK and colleagues conducted ... between 44 to 65, and found a direct association between ... of the thickness of blood vessel walls that is used ...
... Danish researchers, in their new studies have concluded that ... suffer from a serious heart condition when compared to ... ,Research by Kirsten Melgaard Nielsen, Ph.D., and colleagues, of ... after obtaining data on 138,000 adults between the ages ...
Cached Medicine News:Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Dust mites use Duvets as their Haven 2Health News:Long Legs Reduces The Chances Of Heart Disease 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, which ... new generation unites the well-established advantages ... range of additional innovations which guarantee ... sedimentation rate. Cost effectiveness is an ...
... ESR analyzer that brings about ... pipettes. Up to 40 test ... or bach, with automated mixing. ... for back-up support or to ...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: